FY2025 EPS Estimates for Assertio Raised by HC Wainwright

Assertio Holdings, Inc. (NASDAQ:ASRT) – Stock analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Assertio in a note issued to investors on Monday, January 5th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($5.79) per share for the year, up from their prior forecast of ($5.85). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Assertio’s current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Assertio’s Q4 2025 earnings at ($3.05) EPS, Q1 2026 earnings at ($2.28) EPS, Q2 2026 earnings at $0.14 EPS, Q3 2026 earnings at $0.54 EPS and FY2026 earnings at ($0.28) EPS.

ASRT has been the subject of several other reports. Zacks Research upgraded shares of Assertio from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assertio in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Assertio to a “buy” rating in a research report on Saturday, November 22nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Assertio has an average rating of “Moderate Buy” and an average price target of $30.63.

Assertio Stock Performance

NASDAQ ASRT opened at $9.31 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.43 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $59.77 million, a price-to-earnings ratio of -2.00 and a beta of 0.61. The firm’s 50 day simple moving average is $10.94 and its 200 day simple moving average is $11.47. Assertio has a 1 year low of $7.65 and a 1 year high of $15.15.

Assertio (NASDAQ:ASRT) last announced its quarterly earnings data on Monday, November 10th. The company reported $1.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $2.85. The firm had revenue of $49.46 million for the quarter, compared to the consensus estimate of $27.02 million. Assertio had a negative net margin of 21.06% and a negative return on equity of 26.99%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ASRT. Nantahala Capital Management LLC grew its position in Assertio by 4.4% in the 2nd quarter. Nantahala Capital Management LLC now owns 8,810,073 shares of the company’s stock valued at $5,649,000 after purchasing an additional 370,311 shares during the period. GSA Capital Partners LLP lifted its stake in shares of Assertio by 536.0% in the third quarter. GSA Capital Partners LLP now owns 381,584 shares of the company’s stock valued at $336,000 after buying an additional 321,584 shares in the last quarter. Perritt Capital Management Inc grew its holdings in shares of Assertio by 51.6% during the third quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock valued at $309,000 after buying an additional 119,281 shares during the last quarter. Belpointe Asset Management LLC bought a new stake in shares of Assertio during the first quarter worth about $65,000. Finally, Vanguard Group Inc. raised its holdings in shares of Assertio by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,425,543 shares of the company’s stock worth $3,899,000 after acquiring an additional 41,332 shares during the last quarter. 48.96% of the stock is owned by institutional investors.

Assertio Company Profile

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.